Repligen (RGEN) Receives Research Grants to Support Friedreich's Ataxia Development Program
More News related to RGEN
- Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
- Repligen Reports Second Quarter Fiscal Year 2009 Financial Results
- Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
- Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST
- Repligen (RGEN) Receives Research Grants to Support Friedreich's Ataxia Development Program
More News related to Corporate News
- Liquidity Services (LQDT) Tops Q4 View By 2c; Guides Higher; Announces A $10M Buyback
- PRIMEDIA (PRM) Announces $5M Share Buyback Program
- Servidyne (SERV) Declares $0.038/Share Qtr. Dividend; Raises Buyback to 100K Shares
- Chubb (CB) Declares Dividend, 20M Share Buyback
- American Physicians Capital (ACAP) Adds $10M to Rule 10b5-1 Repurchase Plan
Repligen Corporation (Nasdaq: RGEN) announced that Repligen has received $1.125 million in research grants to support the development of new treatments for Friedreich's ataxia. The grants are comprised of $1 million from the Muscular Dystrophy Association (MDA) and $125,000 from the Friedreich's Ataxia Research Foundation (FARA) and the National Ataxia Foundation (NAF). The grants will further the development, characterization and selection of a drug candidate for human clinical trials as well as support the development of tools ("biomarkers") to monitor the desired biological impact of the drugs in clinical trials.
Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders.
Related Categories
Corporate NewsStocks Mentioned
-0.25Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
